Mean DAS28 after 6–24 months for completers of the initial biological therapy and for all patients (ITT analysis)
| Completers only | All patients | ||||||
| n | Mean of DAS28 at 6, 12, 18 and 24 months (95% CI) | Mean of DAS28 at 6, 12, 18 and 24 months (95% CI) | n | Mean of DAS28 at 6, 12, 18 and 24 months (95% CI) | Mean of DAS28 at 6, 12, 18 and 24 months (95% CI) | ||
| Unadjusted | Adjusted* | Unadjusted | Adjusted* | ||||
| ETA/MTX | 182 | 3.3 (3.2 to 3.5) | 3.3 (3.2 to 3.5) | 305 | 3.8 (3.7 to 4.0) | 3.8 (3.7 to 3.9) | |
| ETA/LEF | 49 | 3.4 (3.1 to 3.7) | 3.5 (3.2 to 3.7) | 78 | 3.9 (3.6 to 4.2) | 3.8 (3.6 to 4.1) | |
| ADA/MTX | 156 | 3.4 (3.2 to 3.6) | 3.4 (3.3 to 3.6) | 274 | 3.8 (3.6 to 3.9) | 3.8 (3.6 to 3.9) | |
| ADA/LEF | 40 | 3.5 (3.2 to 3.8) | 3.5 (3.2 to 3.8) | 80 | 3.9 (3.6 to 4.2) | 3.9 (3.7 to 4.2) | |
| INF/MTX | 112 | 3.4 (3.4 to 3.8) | 3.5 (3.3 to 3.7) | 250 | 4.0 (3.8 to 4.2) | 3.8 (3.7 to 4.0) | |
| INF/LEF | 19 | 4.2 (3.7 to 4.7) | 4.0 (3.6 to 4.4) | 54 | 4.4 (4.0 to 4.7) | 4.2 (3.9 to 4.5) | |
*Means adjusted for disease activity score based on 28 joint counts (DAS28) at baseline, function, percentage of men, previous biological therapy, year of follow-up, year of study entry; see Statistics section. ADA, adalimumab; ETA, etanercept; INF, infliximab; ITT, intent-to-treat; LEF, leflunomide; MTX, methotrexate.